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A series of clinical isolates of herpes simplex virus type 2 were taken from a patient with chronic lymphocytic 
leukemia. Acyclovir (ACV) susceptibility assays revealed that some isolates were resistant to ACV and 
cross-resistant to ganciclovir but not to phosphonoacetic acid. The nature of the resistance was examined 
further. A number of cloned variants were generated, and thymidine kinase and DNA polymerase assays were 
carried out. Variants that were resistant to ACV were found to be thymidine kinase deficient. Evidence for
*
alteration in the DNA polymerase was not found when ACV triphosphate or phosphonoacetic acid was used as 
the inhibitor. In vivo studies with the plaque-purified viruses showed that ACV resistance was associated with 
a reduced neurovirulence. In a zosteriform model, virus resistant to ACV was unable to induce secondary 
spread in the same dermatome, to invade the peripheral nervous system or the central nervous system, or to 
establish latent infections.
The efficacy and selectivity of acyclovir (ACV) has re­
sulted in its becoming the drug of choice for the treatment of 
herpes simplex virus (HSV) and varicella-zoster virus infec­
tions (13). Nevertheless, concern has been expressed about 
the potential for resistant virus to appear in ACV-treated 
individuals. Laboratory investigations with HSV have re­
vealed that resistance to ACV may develop under specific 
selection pressure. Characterization of laboratory-generated 
resistant mutants indicates that resistance arises as a result 
of loss or alteration of thymidine kinase (TK) activity or 
alteration in the virus DNA polymerase (4, 15, 18, 23). Virus 
isolates recovered from clinical trials of ACV in immuno­
competent patients have been monitored and have shown 
little evidence of alteration in their susceptibility to ACV (2, 
8). However, there have been a small number of reports of 
the isolation of virus with reduced susceptibility, particularly 
from bone marrow transplant patients and leukemic patients 
undergoing induction chemotherapy (2, 3, 8, 9, 16, 24, 30).
HSV clinical isolates with reduced susceptibility to ACV 
have resulted from a deficiency or alteration in virus TK (5), 
with one recent exception, when virus with an altered DNA 
polymerase was identified (7, 22). There is no clear indica­
tion of the significance of the isolation of resistant virus or its 
relationship with the clinical course of a disease (12, 20), 
there often being no correlation between the clinical re­
sponse to ACV and the isolation of resistant virus (2, 11). 
Virus recovered during recurrences subsequent to an epi­
sode from which resistant virus was isolated have all re­
tained a phenotype reflecting the susceptibility of the original 
infecting virus which initiated latency (1, 25, 27). Thus, such 
recurrences would be expected to be amenable to ACV 
therapy. Evidence in animal models with mutants displaying 
a TK-dcficient phenotype suggest that the resistant clinical 
isolates recovered would not establish latent infections and 
would thus be unlikely to be transmitted (10, 14, 29).
Few reports detailing the susceptibility of sequential iso­
lates from one patient have been made (21, 24). During
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routine susceptibility monitoring, isolates from a 75-year-old 
male with chronic lymphocytic leukemia who received mul­
tiple courses of ACV therapy for persistent perianal herpes 
were characterized. These isolates exhibited an unusual 
profile of susceptibility to ACV. Two early isolates were 
susceptible to ACV and ganciclovir {9-([2-hydroxy-l-(hy- 
droxymethyl)ethoxy]methyl)guanine}, whereas subsequent 
isolates taken during prolonged exposure to ACV w'ere less 
susceptible. The aim of the work described in this report was 
to determine the susceptibility of all the isolates received and 
relate this to their biochemical properties, their pathogenic­
ity, and the ability of the isolates to cause latent infections in 
animal models.
MATERIALS AND METHODS
Patient details. The patient was a 75-year-old male w'ith 
chronic lymphocytic leukemia, who developed a severe 
perianal herpesvirus infection in October 1982. T his was 
successfully treated with intravenous (i.v.) ACV at 1.5 g per 
day, given for 5 days. The infection recurred in February 
1983 and was again successfully treated w'ith i.v. ACV. Over 
the next 6 months, the lesions gradually recurred and oral 
ACV at 1 g per day was given, but no clinical improvement 
was observed and virus was isolated (Fig. 1). Treatment was 
increased to i.v. ACV at 2.25 g per day, but was again 
unsuccessful. A course of topical phosphonoformic acid was 
given, but the patient remained culture positive. By January 
1984, the lesions had extended to the left thigh and i.v. ACV 
at 3 g per day was given, which ameliorated the lesions. In 
February 1984, cecal carcinoma was diagnosed and a hemi­
colectomy was performed. A relapse of the herpesvirus 
infection in May 1984 was treated with i.v. ACV at 2.25 g per 
day, with limited success. Finally, oral ACV at 2.4 g per day 
was prescribed, but the patient remained culture positive. 
Further virus isolates were unobtainable. In September 1984 
he received courses of Leukeran (Burroughs Wellcome Co., 
Research Triangle Park, N.C.) and prednisone for his leuke­
mia, but he died in October 1984.
Virus isolates. Virus isolates were cultured in human 
embryonic fibroblasts and received as frozen cell culture 
extracts in our laboratory. They were grown in Vero cells













HSV —IN FECTION D> c>
TREATMENT ACV ACV ACV ACV
ROUTE i.v. i.v. oral i.v.
DAILY DOSE 1.5 g 1.5 g 1 g 2.25 g
VIRUS ISOLATION + + + + + +
ACV SENSITIVITY s s R R
ISOLATE IDENTITY 1 2 3 4
ACV PFA ACV 
oral i.v.
1 9 3 g








2.25 g 2.4 g 
+ + + + +
FIG. 1. Patient details.
(Flow Laboratories, Irvine, Scotland), and the resultant 
crude virus extracts were then aliquoted and stored at 
-70°C. Susceptibility assays were performed on pass 2 or 3 
material only. The type 2 strains BRY, BRY TK , 186R (a 
phosphonoacetic acid fPAAJ-resistant type 2 herpesvirus), 
and its parent strain 186 were used as controls.
Compounds for antiviral assays. ACV and ganciclovir were 
prepared by the Wellcome Chemical Works, Dartford, En­
gland. and phosphonoacetic acid (PAA) was supplied by P. 
Furman (Burroughs Wellcome Co.). All compounds were 
prepared as 1 or 10 mM (PAA) solutions in deionized water, 
filter sterilized, aliquoted, and stored at -20°C.
Viral susceptibility assays. A standard plaque reduction 
assay was used to determine the susceptibility of the isolates 
(6, 27). Preformed Vero cell monolayers in Falcon 24 multi­
well plates (Becton Dickinson, Oxford, England) were in­
fected with 100 to 150 PFU per well. After a 1-h adsorption 
at 37°C in a 5% C 0 2 atmosphere, the wells were overlaid 
with serial twofold dilutions of the test compound in 1% 
carboxymethyl cellulose containing 10% Glasgow modified 
Eagle medium (Northumbria Biologicals, Cramlington, 
England), 2% newborn calf serum (GIBCO. Paisley, Scot­
land), 0.11% sodium bicarbonate, 2 mM L-glutamine 
(GIBCO), and 100 U each of penicillin and streptomycin 
(GIBCO) per ml. After a 72-h incubation, the cells were fixed 
and stained with 0.5% methyl violet. Plaque counts were 
expressed as a percentage of the virus control and used to 
construct dose-response lines from which the 50% inhibitory 
concentrations were determined from the resultant linear 
regression lines.
Production of cloned variants. Serial 0.5-log dilutions of 
each isolate were used to infect 96-well plates (Falcon) 
seeded with Vero cells. The cells were overlaid and incu­
bated as before. Cultures were observed closely for plaque 
formation; wells containing single plaques were marked. 
After a further 24 to 48 h, any secondary plaque formation 
was noted and single plaques were picked. Infected cells 
were sonicated, and an aliquot was added to Vero cell 
monolayers. Crude virus infected stocks were prepared as 
for the parent isolates, and sensitivity assays were carried 
out. Two clones from each isolate were selected for further 
analysis.
TK assay. Crude enzyme extracts were prepared in TK- 
negative BHK (BuBHK) cells. The measurement of the 
nucleoside-phosphorylating activity was based on published 
methodology (17). The extract was prepared following an 
18-h incubation of cells infected with 10 PFU per cell. 
Infected cells were disrupted in 0.01 M Tris buffer (pH 7.4)
and sonicated, and aliquots were assayed at 37°C in 0.02 M 
phosphate buffer with 5 mM magnesium chloride, 5 mM 
ATP, and 30 |xM l14CJthymidine (Amersham International 
pic, Amersham, England) as substrate. The conversion of 
thymidine to phosphorylated derivatives was expressed as 
picomoles of phosphorylated product per 10'"' or 10h cells.
DNA polymerase assay. A crude enzyme extract was 
prepared in BuBHK cells, as for the TK assay, infected cells 
being suspended in 250 mM phosphate buffer (pH 7.5) with 1 
mM EDTA, 2 mM dithiothreitol, and 1 mM phenylmethyl- 
sulfonyl fluoride (Sigma, Poole, England). The reaction mix 
contained 50 mM Tris buffer (pH 7.5), 200 mM KCI, 4 mM 
MgCU, 0.5 mM dithiothreitol, 0.0125 mg of activated calf 
thymus DNA (Lome Diagnostics Ltd., Bury St. Edmunds, 
England), and 2 mM TTP, dATP, and dCTP. with 5 fiM 
[8-?H]dGTP at 50 [xCi/ml (Amersham), plus 5 fxl of enzyme. 
The total volume of 100 |xl contained ACV triphosphate 
(ACV-TP) or PAA as inhibitor. ACV-TP was used at 0. 0.05, 
0.5, 5.0, and 10.0 |jlM. After incubation for 5 min at 37°C, 
50-fjJ aliquots were spotted onto DE81 disks (Whatman, 
Maidstone, England), which were washed three times with 
0.3 M ammonium formate made pH 7.8 with ammonia. 
Radioactivity was determined by scintillation counting with 
Optiscint Safe scintillant (LKB, Croydon, England).
Restriction enzyme analysis. DNA from selected clones 
was prepared by infecting 10s BHK21 cells with 0.1 PFU per 
cell. After a 48-h incubation, cells were lysed in 10 mM Tris 
(pH 8.0) with 10 mM EDTA and 0.25% Triton X-100 
(Sigma). Following gentle mixing. 0.2 M NaCl was added, 
and nuclei were pelleted at 450 x g. The supernatant was 
treated with 0.2%' sodium dodecyl sulfate and 1 mg of 
pronase per ml and incubated at 37°C for 4 to 6 h. The DNA 
was extracted twice with phenol-chloroform and once with 
chloroform and then precipitated with 2.5 volumes of etha­
nol at -20°C. After the DNA had been pelleted, it was dried, 
dissolved in 400 \x\ of water, and mixed with 400 [xl of 5 M 
LiCI to precipitate RNA. After centrifugation, the superna­
tant was mixed with ethanol at -70°C. The DNA was spun 
down and dissolved in TE (10 mM Tris, 1 mM EDTA), with
0.2 M NaCl added. After the nucleic acid had been precip­
itated with 2.5 volumes of cold ethanol, the DNA was 
spooled and dissolved in 200 \x\ of TE. The DNA was 
digested with a number of restriction enzymes (GIBCO/ 
Bethesda Research Laboratories) and analyzed on 0.8%' 
agarose gels (Miles Laboratories, Slough, England).
In vivo studies. Studies of neurovirulence were performed 
with groups of 10 CD1 mice weighing 15 to 18 g (Charles 
River Breeding Laboratories, Manston, Kent, England). The
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TABLE 1. Preliminary characterization of the HSV isolates
Isolate
Susceptibility 
(IC<„ ||j.M|)" to: Neurovirulence







1 1.0 3.0 68 < 10 +
2.5 5.0 160 < 10 +
3 170 >600 130 1,000 N D ‘
4 220 440 73 > 1,000 ND
5 260 >600 190 1,000 ND
6 14 23 74 < 10 +
7 1.2 1.5 62 < 10 +
TABLE 2. ACV susceptibilities of the cloned variants
of the parent isolates
" ICso. 50% inhibitory concentration.
h Ncurovirulcncc was determined following intracerebral inoculation of
mice. L D S(), 509f lethal dose. 
' ND . Not detectable.
mice were inoculated with serial 10-fold dilutions of virus by 
the intracerebral route, and survival times were recorded. 
Pathogenicity was further studied by using a zosteriform (26) 
model of HSV in inbred BALB/c mice (Animal Health 
Control, Wellcome Research Laboratories, Beckenham, 
England). A primary infection was induced on the depilated 
upper flank by scarification through 10 (jlI of virus suspension 
containing 10f> PFU. The development of secondary zoste- 
riform spread of infection and subsequent survival times 
were recorded.
RESULTS
Viral susceptibility assays, (i) Isolates. The isolates were 
identified as being HSV-2, and this was confirmed subse­
quently by restriction enzyme analysis. Results from at least 
two separate plaque reduction assays against ACV, ganci­
clovir. and PAA are summarized in Table 1. Isolates 1 and 2, 
taken before the courses of ACV therapy, were susceptible 
to ACV, ganciclovir, and PAA, although isolate 2 was two- 
to threefold less susceptible to ACV than isolate 1 was. 
These values, however, fall within the ranges seen for 
susceptible HSV-2 isolates in assays in Vero cells (5). 
Isolates 3, 4, and 5, taken during the protracted period of 
HSV infection, were resistant to ACV and ganciclovir. 
During a period when ACV therapy was stopped, a further 
isolate (no. 6) was obtained, which was of increased suscep­
tibility to ACV and ganciclovir and was also susceptible to 
PAA. The final isolate, isolate 7, taken before a successful 
course of i.v. ACV treatment, was susceptible to all com­
pounds tested.
(ii) Plaque-purified clones. Plaque-purified clones from 
each isolate were produced, and their susceptibilities to 
ACV were determined. The number of resistant clones 
found compared with the total number produced for each 
isolate is summarized in Table 2. Isolates 1 and 6 were 
clearly mixtures of ACV-susceptible and ACV-resistant vi­
ruses, whereas all the clones from isolates 3, 4, and 5 were 
resistant to ACV. For isolates 2 and 7, all the clones were 
susceptible to ACV. Two clones from each isolate were 
selected and further characterized. The susceptibility data 
(Table 3) give the average 50% inhibitory concentrations for 
at least two separate assays. For isolates 1 and 6, a suscep­
tible and a resistant clone were evaluated. Clones resistant 
to ACV were correspondingly resistant to ganciclovir, al­
though for 4A and 5B, resistance to ganciclovir was four 
times that of resistance to ACV. Despite some variability, 
the data for PAA showed that all the clones tested were 
susceptible to this compound.








" Resistance is defined as 50% inhibitory concentrations greater than 
10 p-M.
TK assay. The TK phosphorylating activity of the seven 
isolates is given in Table 1. For the three ACV-resistant 
isolates, isolates 3, 4. and 5. no activity was detected. With 
the three susceptible isolates, isolates 1, 2, and 7, activity 
comparable to that of wild-type controls was seen. Isolate 6, 
of reduced susceptibility, showed only 20%’ TK activity 
compared with the ACV-susceptible isolates (data not 
shown). Clones from this isolate were of mixed susceptibility 
to ACV (Table 2), which may explain the low TK activity 
seen. The TK activity of all the clones investigated is given 
in Fig. 2. As with the parent isolates, clones resistant to 
ACV showed no detectable TK activity, whereas for the 
susceptible variants, wild-type TK levels were expressed. 
The TK-negative control BRY TK was included and 
showed activity equivalent to that of the mock-infected 
extract. Mock-infected and TK-negative extracts showed 
somewhere between 0 and 5% of the wild-type activity and 
thus represent the limits of detection of the assay.
DNA polymerase assay. The susceptibilities of the DNA 
polymerase preparations, with either ACV-TP or PAA as 
inhibitor and expressed as 50% inhibitory concentrations, 
are summarized in Table 4. The HSV-2 virus 186 and its 
PAA-resistant variant 186R are included as controls. A 
10-fold decrease in the susceptibility of the 186R DNA













PAA Primary Secondary £cmcit>
1A 260 320 47 1 X 102 ND' —
IB 3.2 3.6 24 3.1 X 1()J 3.,2 X 104 +
2 A 1.8 3.5 89 5.7 X 103 1 mam 1.0 X 103 +
2E 1.1 2.6 150 2.8 X 103 6 ,.2 X 102 +
3B, >400 >600 82 1.2 X 104 ND —
31 140 130 74 5.7 X 1()2 ND —
4A 120 >400 60 4.0 X 102 ND —
4E 52 90 44 3.2 X 1()2 ND —
5 A 470 410 110 3.5 X 102 ND —
5B 52 >250 64 1.5 X 102 ND —
6C 63 NT '7 86 4.7 X 1()2 ND —
6E 1.3 2.0 66 3.5 X 103 1 mm \.6 X 103 +
7FB 4.2 3.1 87 9.4 X 102 4 .3 X 102 +
7GA 3.0 NT NT 6.3 X 102 1 .2 X 102 +
BRY 0.5 0.6 52 3.8 X 103 1 X 104 +
BRY TK 51 >80 56 3.0 X 102 ND —
" IC 5„. 50% inhibitory concentration. 
h Zosteriform model.
' ND . Not detectable.
J NT. Not tested.































2. TK activity of pairs of selected cloned variants
polymerase to PAA was seen. Shifts were not seen with any 
enzyme assayed from the selected clones. When ACV-TP 
was substituted for PAA in the assay, again no changes were 
seen. The relative susceptibility of these crude enzyme 
preparations to both ACV-TP and PAA is further evidence 
that the resistance seen in vitro is due to no or low expres­
sion of TK.
Restriction enzyme analysis. DNA was extracted from four
V* *
clones and digested with BglII. EcoRI. and Kpn\.
Analysis of the resulting fragments revealed no significant 
differences between the viruses. The changes that were seen 
were minor and mapped to the variable junction and terminal 
repeat regions. These changes are frequently seen, particu­
larly when a series of isolates from a single patient is 
analyzed (19).
Neurovirulence. The pathogenicity of the seven isolates in 
mice was determined following intracerebral inoculation. 
The 50% lethal doses (Table 1) for the ACV-susceptible
TABLE 4. Inhibition of DNA polymerase from selected clones
bv ACV-TP and PAA
Isolate
Susceptibility of DNA  polvmer;







3 B 2 0.17 1.0
31 0.14 3.0
4 A 0.11 1.4
4E 0.05 1.6








" IC S0. 50% inhibitory conccntralion. 
h NT. Noi tested.
isolates, isolates 1, 2. 6, and 7, were less than 10 PFU. For 
the three resistant isolates, isolates 3. 4, and 5, the 50% 
lethal doses were up to 100-fold greater. These results 
correlate with other reports, showing that increased resis­
tance to ACV is associated with a reduction in virulence to 
mice inoculated by this route (14).
Zosteriform model. A cutaneous primary infection was 
induced on the upper flanks of mice and subsequently 
monitored for up to 7 days. Clinical observations were made, 
and animals were sacrificed on day 5 for removal of skin 
samples from primary and secondary sites. Clones suscep­
tible to ACV produced a secondary infection from which 
virus was readily detected by titration of extracts of excised 
skin samples in Vero cells (Table 3). Infection with the 
ACV-resistant clones resulted in only a mild primary infec­
tion in mice at the site of inoculation. Studies with a TK 
deletion mutant in our laboratory showed this mutant to be 
weakly neurovirulent when inoculated onto the flank. How­
ever, although a primary infection was established at the 
inoculation site, there was no evidence of secondary spread.
DISCUSSION
We have reported in this paper the biological and bio­
chemical characteristics of a series of HSV-2 clinical isolates 
from a severely immunocompromised patient. Few reports 
exist giving such data on sequential isolates from one pa­
tient. Two early disease episodes were controlled with 
prompt aggressive therapy, but subsequently, during an 
indolent episode of perianal disease, ACV-resistant virus 
was isolated. A change in therapy did ameliorate the infec­
tion, but the patient remained culture positive until he died. 
Consistent with other reports (3, 9, 16, 24, 28, 30), resistance 
may occur in immunocompromised patients who progress to 
persistent disease, particularly if ACV therapy is delayed or 
insufficiently aggressive.
The susceptibility data revealed that isolates taken during 
protracted courses of oral therapy were resistant to the 
TK-activated compounds ACV and ganciclovir. Studies of 
enzyme extracts of the parental virus showed that resistance 
was probably due to an inability of the virus to express TK 
as measured in assays of thymidine conversion. All viruses 
remained susceptible to PAA, suggesting that resistance was 
unlikely to result from an alteration in the viral DNA 
polymerase. This was confirmed when enzyme extracts were 
found to be sensitive to both ACV-TP and PAA. Had there 
been changes in the sensitivity of the enzyme to inhibition by 
ACV-TP or PAA, this would be indicative of an alteration at 
the DNA polymerase locus (22).
The nature of the resultant virus populations was further 
examined by producing a number of plaque purified variants 
of isolates 1 to 7. Biological and biochemical characteriza­
tion of selected cloned viruses revealed that pretreatment 
isolates consisted of a mixture containing approximately 
one-third TK-deficient viruses. Furthermore, plaque purifi­
cation of the last resistant isolate showed this to consist of 8 
of 19 TK-deficient clones (Table 2). The extended courses of 
ACV therapy have exerted a selection pressure on this 
mixed virus population, resulting in all plaque-purified vi­
ruses being shown to be TK deficient during the resistant 
phase. Significantly, disease was later amenable to therapy 
following the removal of the selection pressure, in that ACV 
administration was stopped for 3 weeks and topical phos- 
phonoformic acid was administered for 7 days. This initiated 
a partial restoration of a wild-type population (isolates 6 and 
7), which was successfully controlled with high i.v. doses of 
ACV.
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Studies of mice confirmed that the recovered ACV-resis- 
tant, TK-deficient viruses had low virulence, failing to 
invade the peripheral nervous system and subsequently the 
central nervous system or to establish latent infection fol­
lowing infection of the llank. Furthermore, neurovirulence 
was decreased by 3 orders of magnitude following intrace­
rebral inoculation. These findings are consistent with those 
of previous workers, who found that TK-deficient virus is 
less virulent, less likely to establish a latent infection, and 
less neurovirulent than wild-type virus (10, 14, 29).
The isolates were confirmed as being HSV-2 by restriction 
endonuclease digestion. Analysis of the resulting band pat­
terns was indicative of infection by a single strain, but these 
results should he interpreted with care (19). By comparing a 
number of isolates from a single patient, it could be seen that 
there were a number of changes in the restriction patterns 
but that most changes occurred in the variable terminal and 
subterminal regions (19). (Unfortunately, the last isolates 
were unavailable for analysis.)
In conclusion, the initial high-dose i.v. therapy given 
during the first disease episode successfully ameliorated this 
HSV infection. When the infection recurred, therapy was 
delayed, and hence when oral treatment was prescribed, 
success was limited. Resistant virus was isolated which 
persisted despite more aggressive i.v. therapy. Subsequent 
removal of the selection pressure and possibly the introduc­
tion of phosphonoformic acid resulted in the reestablishment 
of a susceptible virus population which responded to high- 
dose i.v. ACV therapy. Extended periods of ACV therapy, 
particularly in immunocompromised patients, may lead to 
treatment failure if resistant virus is selected. However, the 
correlation between in vitro susceptibility and response to 
therapy is not always clear (12, 20). With this patient, 
interruption of ACV therapy and possibly the introduction of 
a non-TK-activated form of antiviral therapy (phosphono- 
formic acid) resulted in a further course of i.v. ACV therapy, 
successfully eliminating the HSV infection. The last isolate 
recovered at this time was susceptible to ACV.
ACKNOWLEDGMENTS
We thank G. Darby for constructive criticism. V. Parmar for 
performing the virus susceptibility assays, and P. Ward for typing 
the manuscript.
LITERATURE CITED
1. Barry, I). VV., and S. NusinofT-Lehrman. 1984. Viral resistance 
in clinical practice: summary of 5 years experience with acyclo­
vir. p. 269-270. In R. Kono and A. Nakajima (ed.). Proceedings 
of the International Symposium on Pharmacological and Clini­
cal Approaches to Herpes Viruses and Virus Chemotherapy. 
Oiso. Japan. Elsevier Science Publishers BV, Amsterdam.
2. Barry, I). W ., S. NusinofT-Lehrman, N. M. Ellis, k . K. Biron, 
and P. A. Furman. 1985. Viral resistance, clinical experience. 
Scand. J. Infect. Dis. Suppl. 47:155-164.
3. Burns, W. H., R. Saral, G. W . Santos, (). L. Laskin, P. S. 
Lietman, C. McLaren, and D. W. Barry. 1982. Isolation and 
characterization of resistant herpes simplex virus after acyclovir 
therapy. Lancet i:421-423.
4. Coen, I). M., and P. A. Schaffer. 1980. Two distinct loci confer 
resistance to acycloguanosine in herpes simplex virus type 1 . 
Proc. Natl. Acad. Sci. USA 77:2265-2269.
5. Collins, P. 1988. Viral sensitivity following the introduction of 
acyclovir. Am. J. Med. 85(Suppl. 2A):129-134.
6. Collins, P., G. Appleyard, and N. M. Oliver. 1982. Sensitivity of 
herpes virus isolates from acyclovir clinical trials. Am. .1. Med. 
73:380-382.
7. Collins, P., B. A. Larder, N. M. Oliver, S. Kemp, I. W. Smith,
and G. Darby. 1989. Characterization of a DNA polymerase 
mutant of herpes simplex virus from a severely immunocom­
promised patient receiving acyclovir. J. Gen. Virol. 70:375-382.
8. Collins, P., and N. M. Oliver. 1986. Sensitivity monitoring of 
herpes simplex isolates from patients receiving acyclovir. J. 
Anlimicrob. Chemother. 18(Suppl. B): 103—112.
9. Crunipacker, C. S., L. E. Schnipper, S. I. Marlow, P. N. 
Kowalsky, B. .1. Hershey, and M. J. Levin. 1982. Resistance to 
antiviral drugs of herpes simplex virus isolated from a patient 
treated with acyclovir. N. Engl. J. Med. 306:343-346.
10. Darby, G., II. .1. Field, and S. A. Salisbury. 1981. Altered 
substrate specificity of herpes simplex virus thymidine kinase 
confers acyclovir resistance. Nature (London) 289:81-83.
11. Dekker, I)., M. N. Ellis, C. McLaren, G. Hunter, J. Rogers, and 
I). VV. Barry. 1983. Virus resistance in clinical practice. J. 
Anlimicrob. Chemother. 12:137-152.
12. Ellis, M. N., and I). VV. Barry. 1985. Oral acylovir therapy of 
genital herpes simplex virus type 2 infections in guinea pigs. 
Anlimicrob. Agents Chemother. 27:167-171.
13. Fiddian, A. P., I). Brinden, .1. M. Yeo, and E. A. Hickmott. 1984. 
Acyclovir: an update of the clinical applications of this anti- 
herpes agent. Antiviral Res. 4:99-117.
14. Field, II. .1., and G. Darby. 1980. Pathogenicity in mice of strains 
of herpes simplex virus w hich are resistant to acyclovir in vitro 
and in vivo. Anlimicrob. Agents Chemother. 17:209-216.
15. Field, H. J., G. Darby, and P. Wildy. 1980. Isolation and
*  w v
characterization of acyclovir-resistant mutants of herpes sim­
plex virus. .1. Gen. Virol. 49:115-124.
16. Mann, I. M., H. G. Prentice, H. A. Blacklock, M. G. R. Ross, I). 
Brigden, A. E. Rosling, C. Burke, I). II. Crawford, VV. Brumfitt, 
and A. V. Hofibrand. 1983. Acyclovir prophylaxis against 
herpes virus infections in severely immunocompromised pa­
tients: randomised double blind trial. Br. Med. J. 287:384—388.
17. Klemperer, H. G., G. R. Haynes, VV . I. H. Shedden, and I). H. 
Watson. 1967. A virus specific thymidine kinase in BHK21 cells 
infected with herpes simplex virus. Virology 31:120-128.
18. Larder, B. A., and G. Darby. 1985. Selection and characteriza­
tion of acyclovir-resistant herpes simplex virus type 1 inducing 
altered DNA polymerase activities. Virology 146:262-271.
19. Maitland, N. I. VV. Smith, J. F. Peutherer, I). H. H. 
Robertson, and K. VV. Jones. 1982. Restriction endonuclease 
analysis of DNA from genital isolates of herpes simplex virus 
type 2. Infect. Immun. 38:834-842.
20. NusinofT-Lehrman, S., J. M. Douglas, L. Corey, and I). VV. 
Barry. 1986. Recurrent herpesvirus disease during suppressive 
oral acyclovir therapy. Correlation of clinical outcome with in 
vino drug sensitivity. Ann. Intern. Med. 104:786-790.
21. NusinofT-Lehrman, S., E. L. Hill, J. F. Rooney, N. M. Ellis,
I). VV. Barry, and S. E. Straus. 1986. Extended acyclovir 
therapy for herpes genitalis: changes in virus sensitivity and 
strain variation. .1. Anlimicrob. Chemother. 18(Suppl. B):85-94.
22. Parker, A. C., .1. L. O. Craig, P. Collins, and N. Oliver. 1987. 
Acyclovir-resisiant herpes simplex virus infection due to altered 
DNA polymerase. Lancet ii: 1461.
23. Schnipper, L. E., and C. S. Crunipacker. 1980. Resistance of 
herpes simplex virus lo acycloguanosine: the role of the viral 
thymidine kinase and DNA polvmerase loci. Proc. Natl. Acad. 
Sci. USA 77:2270-2273.
24. Sibrack, C. I)., L. T. Gutman, C. M. Wilfet, C. McLaren, M. H. 
St. Clair, P. M. Keller, and I). VV. Barry. 1982. Pathogenicity of 
acyclovir-resisiant herpes simplex virus type 1 from an immu- 
nodeficienl child. J. Infect. Dis. 146:673-682.
25. Sibrack, C. I)., C. McLaren, and I). VV. Barry. 1982. Disease 
and latency characteristics of clinical herpes simplex virus 
isolates after acyclovir therapy. Am. J. Med. 73:372-375.
26. Simmons, A., and A. A. Nash. 1984. Zosteriform spread of 
herpes simplex virus as a model for recrudescence and its use to 
investigate the role of immune cells in prevention of recurrent 
disease. J. Virol. 52:816-821.
27. Straus, S. E., H. E. TakitT, M. Seidlin, S. Bachrach, L. Liniger, 
.1. .1. DiGiovanna, K. A. Western, H. A. Smith, S. NusinofT- 
Lehrman, M. S. Creagh-Kirk, and I). VV. Ailing. 1984. Suppres­
sion of frequently recurring genital herpes. A placebo-conlrolled
640 OLIVER ET AL. A n t i m i c r o b . A g e n t s  C h e m o t m e r .
double-blind trial of oral acvclovir. N. Enel. J. Med. 310: ganglion infection bv thvmidine kinase-necative mutants of
1545-1550. herpes simplex virus. Science 205:915-917.
28. Svennerholm, B., A. Vahlne, Ci. B. Lowhagen, A. Widell, and F. 30. Wade, J. C., C. McLaren, and J. I). Meyers. 19S3. Frequency
Lycke. 1985. Sensitivity of HSV strains isolated before and after and significance of acyclovir-resistant herpes simplex virus
treatment with acyclovir. Scand. J. Infect. Dis. Suppl. 47: isolated from marrow transplant patients receiving multiple
149-154. courses of treatment with acvclovir. J. Infect. Dis. 148:1077—
29. Tenser, R. B., R. L. Miller, and F. Rapp. 1979. Trigeminial 1082.
